Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aging restricts maturation of CXCL13<sup>+</sup> T follicular helper cells in human immunity.

Cell reports·2026

Same author

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Journal for immunotherapy of cancer·2026

Same author

Aging restricts maturation of CXCL13<sup>+</sup> T follicular helper cells in human immunity.

bioRxiv : the preprint server for biology·2026

Same author

Fetal Thymic Expression Defines the Immunogenicity of Tumor Associated Antigens.

bioRxiv : the preprint server for biology·2026

Same author

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.

Blood advances·2026

Same author

The Immune Microenvironment of Transplant Glomerulitis.

Kidney international reports·2025

Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026

Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026

Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026

Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026

Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026

Same journal

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.

Oncoimmunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 10, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Lessons learned from a highly-active CD22-specific chimeric antigen receptor.

Adrienne H Long¹, Waleed M Haso, Rimas J Orentas

¹Pediatric Oncology Branch; National Cancer Institute; Center for Cancer Research; National Institutes of Health; Bethesda, MD USA.

|June 5, 2013

Summary

This summary is machine-generated.

A novel chimeric antigen receptor (CAR) targeting CD22 shows promise for treating B-cell cancers. This CAR effectively targets a specific CD22 epitope, enhancing its therapeutic potential in immunotherapy.

Keywords:

ALL CD22 adoptive immunotherapy leukemia retroviral vectors

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: May 10, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

CD22 is a key target for B-cell malignancy immunotherapies.
Chimeric antigen receptor (CAR) T-cell therapy offers a promising avenue for cancer treatment.

Purpose of the Study:

To develop and evaluate a novel second-generation CAR targeting CD22.
To assess the therapeutic potential of a CD22-targeting CAR for B-cell malignancies.

Main Methods:

Engineering a second-generation CAR derived from the m971 antibody.
Focusing CAR development on targeting a membrane-proximal CD22 epitope.

Main Results:

The developed CAR demonstrates significant therapeutic promise.
The CAR's efficacy is linked to its ability to target a specific CD22 epitope.

Conclusions:

A CD22-targeting CAR, particularly one targeting a membrane-proximal epitope, is a viable immunotherapeutic strategy.
This approach holds potential for treating B-cell malignancies.